vs

Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and MONARCH CASINO & RESORT INC (MCRI). Click either name above to swap in a different company.

Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $136.6M, roughly 1.2× MONARCH CASINO & RESORT INC). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 8.9%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 3.2%).

Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.

The Atlantis Casino Resort Spa is a hotel and casino located in Reno, Nevada, United States. It is owned and operated by Monarch Casino & Resort, Inc. Its three hotel towers have a combined 824 guest rooms and suites. The casino floor spans 64,814 sq ft. Often known simply as "Atlantis," it is one of Reno's most profitable and luxurious properties, competing directly with Peppermill Hotel Casino and Grand Sierra Resort for customers. Nearly $150 million has been spent on upgrading the facility.

ESPR vs MCRI — Head-to-Head

Bigger by revenue
ESPR
ESPR
1.2× larger
ESPR
$168.4M
$136.6M
MCRI
Growing faster (revenue YoY)
ESPR
ESPR
+134.8% gap
ESPR
143.7%
8.9%
MCRI
Faster 2-yr revenue CAGR
ESPR
ESPR
Annualised
ESPR
10.6%
3.2%
MCRI

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ESPR
ESPR
MCRI
MCRI
Revenue
$168.4M
$136.6M
Net Profit
$27.6M
Gross Margin
Operating Margin
50.6%
25.6%
Net Margin
20.2%
Revenue YoY
143.7%
8.9%
Net Profit YoY
38.9%
EPS (diluted)
$0.32
$1.52

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ESPR
ESPR
MCRI
MCRI
Q1 26
$136.6M
Q4 25
$168.4M
$140.0M
Q3 25
$87.3M
$142.8M
Q2 25
$82.4M
$136.9M
Q1 25
$65.0M
$125.4M
Q4 24
$69.1M
$134.5M
Q3 24
$51.6M
$137.9M
Q2 24
$73.8M
$128.1M
Net Profit
ESPR
ESPR
MCRI
MCRI
Q1 26
$27.6M
Q4 25
$22.9M
Q3 25
$-31.3M
$31.6M
Q2 25
$-12.7M
$27.0M
Q1 25
$-40.5M
$19.9M
Q4 24
$4.2M
Q3 24
$-29.5M
$27.6M
Q2 24
$-61.9M
$22.7M
Gross Margin
ESPR
ESPR
MCRI
MCRI
Q1 26
Q4 25
20.8%
Q3 25
26.7%
Q2 25
25.5%
Q1 25
20.2%
Q4 24
2.9%
Q3 24
25.6%
Q2 24
23.0%
Operating Margin
ESPR
ESPR
MCRI
MCRI
Q1 26
25.6%
Q4 25
50.6%
21.3%
Q3 25
-11.4%
27.1%
Q2 25
8.6%
25.8%
Q1 25
-34.0%
20.4%
Q4 24
-6.4%
3.1%
Q3 24
-31.0%
25.5%
Q2 24
3.5%
22.9%
Net Margin
ESPR
ESPR
MCRI
MCRI
Q1 26
20.2%
Q4 25
16.4%
Q3 25
-35.9%
22.1%
Q2 25
-15.4%
19.7%
Q1 25
-62.2%
15.8%
Q4 24
3.1%
Q3 24
-57.2%
20.0%
Q2 24
-83.9%
17.7%
EPS (diluted)
ESPR
ESPR
MCRI
MCRI
Q1 26
$1.52
Q4 25
$0.32
$1.25
Q3 25
$-0.16
$1.69
Q2 25
$-0.06
$1.44
Q1 25
$-0.21
$1.05
Q4 24
$-0.14
$0.25
Q3 24
$-0.15
$1.47
Q2 24
$-0.33
$1.19

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ESPR
ESPR
MCRI
MCRI
Cash + ST InvestmentsLiquidity on hand
$167.9M
$120.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$-302.0M
$549.8M
Total Assets
$465.9M
$725.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ESPR
ESPR
MCRI
MCRI
Q1 26
$120.1M
Q4 25
$167.9M
Q3 25
$92.4M
Q2 25
$86.1M
Q1 25
$114.6M
Q4 24
$144.8M
Q3 24
$144.7M
Q2 24
$189.3M
Stockholders' Equity
ESPR
ESPR
MCRI
MCRI
Q1 26
$549.8M
Q4 25
$-302.0M
$537.7M
Q3 25
$-451.4M
$558.4M
Q2 25
$-433.5M
$539.2M
Q1 25
$-426.2M
$535.6M
Q4 24
$-388.7M
$517.7M
Q3 24
$-370.2M
$513.3M
Q2 24
$-344.2M
$498.4M
Total Assets
ESPR
ESPR
MCRI
MCRI
Q1 26
$725.2M
Q4 25
$465.9M
$712.8M
Q3 25
$364.0M
$725.4M
Q2 25
$347.1M
$705.8M
Q1 25
$324.0M
$712.1M
Q4 24
$343.8M
$691.6M
Q3 24
$314.1M
$671.1M
Q2 24
$352.3M
$672.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ESPR
ESPR
MCRI
MCRI
Operating Cash FlowLast quarter
$45.2M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ESPR
ESPR
MCRI
MCRI
Q1 26
Q4 25
$45.2M
$38.1M
Q3 25
$-4.3M
$56.0M
Q2 25
$-31.4M
$34.1M
Q1 25
$-22.6M
$36.5M
Q4 24
$-35.0M
$37.8M
Q3 24
$-35.3M
$40.3M
Q2 24
$-7.2M
$24.3M
Free Cash Flow
ESPR
ESPR
MCRI
MCRI
Q1 26
Q4 25
$32.2M
Q3 25
$53.5M
Q2 25
$26.0M
Q1 25
$16.6M
Q4 24
$26.2M
Q3 24
$-35.5M
$35.4M
Q2 24
$-7.3M
$11.0M
FCF Margin
ESPR
ESPR
MCRI
MCRI
Q1 26
Q4 25
23.0%
Q3 25
37.5%
Q2 25
19.0%
Q1 25
13.3%
Q4 24
19.5%
Q3 24
-68.7%
25.7%
Q2 24
-9.9%
8.5%
Capex Intensity
ESPR
ESPR
MCRI
MCRI
Q1 26
Q4 25
0.0%
4.2%
Q3 25
0.0%
1.7%
Q2 25
0.0%
5.9%
Q1 25
0.0%
15.8%
Q4 24
0.0%
8.6%
Q3 24
0.3%
3.6%
Q2 24
0.1%
10.4%
Cash Conversion
ESPR
ESPR
MCRI
MCRI
Q1 26
Q4 25
1.66×
Q3 25
1.77×
Q2 25
1.26×
Q1 25
1.84×
Q4 24
8.98×
Q3 24
1.46×
Q2 24
1.07×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ESPR
ESPR

Collaboration Revenue$124.7M74%
Products$43.7M26%

MCRI
MCRI

Casino$79.7M58%
Food and beverage$31.7M23%
Hotel$19.0M14%
Other$6.1M5%

Related Comparisons